ReviewPediatric nephrology (Berlin, Germany)2017
Inflammation in IgA nephropathy.
Review in Pediatric nephrology (Berlin, Germany), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Glucagon-like peptide-1 receptor agonists, inflammation, and kidney diseases: evidence from Mendelian randomization.Renal failure · 2025Pooled it
- Combination therapy with or without warfarin and dipyridamole for severe childhood IgA nephropathy: an RCT.Pediatric nephrology (Berlin, Germany) · 2018Trial
- Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy.Journal of the American Society of Nephrology : JASN · 2018Trial
- IgAN and Risks of Kidney and Cardiovascular Events and Death.Kidney international reports · 2026Article
- The role of the lactate dehydrogenase-to-albumin ratio in predicting renal prognosis in Chinese IgA nephropathy patients: a retrospective cohort study.Frontiers in endocrinology · 2026Article
- Association between neutrophil-to-lymphocyte ratio and early renal function decline in patients with immunoglobulin a nephropathy.Annals of medicine · 2025Observational
- The neutrophil-to-monocyte ratio: a superior inflammatory marker predicting poor prognosis in IgA nephropathy.BMC nephrology · 2025Article
- Targeted-release budesonide: A comprehensive review on its potential in IgA nephropathy.Heliyon · 2025Review
- Prognostic nutritional index as an independent risk factor for disease progression in patients with IgA nephropathy.Frontiers in medicine · 2025Article
- Identification of key necroptosis-related genes and immune landscape in patients with immunoglobulin A nephropathy.BMC nephrology · 2024Article
- The prognostic value of the systemic immune inflammation index in patients with IgA nephropathy.Renal failure · 2024Article
- Identification of GMFG as a novel biomarker in IgA nephropathy based on comprehensive bioinformatics analysis.Heliyon · 2024Article
- Prognostic value of neutrophil-to-lymphocyte ratio on proteinuria remission in patients with idiopathic membranous nephropathy.International urology and nephrology · 2024Article
- Diagnosing and Treating IgAN: Steroids, Budesonide, or Maybe Both?Diagnostics (Basel, Switzerland) · 2024Review
- Are Platelet-Related Parameters Prognostic Predictors of Renal and Cardiovascular Outcomes in IgA Nephropathy?Journal of clinical medicine · 2024Article
- Iron metabolism and chronic inflammation in IgA nephropathy.Renal failure · 2023Review
- Physiological Replication of the Human Glomerulus Using a Triple Culture Microphysiological System.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- The innate immune system in human kidney inflammaging.Journal of nephrology · 2022Review
- Current knowledge of targeted-release budesonide in immunoglobulin A nephropathy: A comprehensive review.Frontiers in immunology · 2022Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunoglobulin A nephropathy (IgAN) is the most frequently occurring primary glomerulonephritis in Caucasian and Asian populations. Nonetheless, therapeutic recommendations are based on weak evidence, large controlled trials are scarce and, in particular, the additional value of immunosuppression beyond comprehensive supportive measures is not well-established. The use of immunosuppressants is supported by experimental insights into IgAN pathogenesis that suggest an autoimmune component in disease development. The so-called "multi-hit" theory comprises multiple steps, starting with defective glycosylation of IgA subclass IgA1 that results in overproduction of galactose-deficient IgA1 (Gd-IgA1), occurrence of anti-Gd-IgA1 autoantibodies, and mesangial deposition of nephritogenic immune complexes. This eventually results in an increased mesangial cell proliferation, inflammatory responses, and complement activation. Recent genome-wide association studies have identified several susceptibility genes, many of which support the "multi-hit" concept. In light of these discoveries, it is astonishing that the vast majority of adult IgAN patients obviously do not need and/or benefit from immunosuppressive therapies in the first place. In fact, a number of supportive measures are highly effective in reducing the risk for disease progression in many patients. These measures need to be optimized before immunosuppression should be considered at all. In this review we focus on the underlying pathogenetic cornerstones and the central question of whether systemic inflammation in adult IgAN patients should be treated. Treatment options in children with IgAN are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.